Fortas, Feriel
Loi, Barbara
Centorrino, Roberta
Regiroli, Giulia
Ben-Ammar, Rafik
Shankar-Aguilera, Shivani
Yousef, Nadya
De Luca, Daniele http://orcid.org/0000-0002-3846-4834
Article History
Received: 19 July 2021
Revised: 5 October 2021
Accepted: 19 October 2021
First Online: 4 November 2021
Declarations
:
: Approved by the “Commission d’Ethique de la SRLF”—n.21/33.
: Obtained from parents or guardian upon NICU admission.
: Obtained from parents of the recorded neonate.
: Prof. De Luca has received research and educational grants from Chiesi Pharmaceuticals S.p.A. and ABBVIE Inc. He served as lecturer for Airway Therapeutics, Chiesi Pharmaceuticals S.p.A. and ABBVIE Inc. Finally, he has been member of advisory boards for Chiesi Pharmaceuticals S.p.A., ABBVIE Inc. and OPHIREX Inc. He is titular of an equity option of OPHIREX Inc. Dr. Shankar-Aguilera and Yousef received a travel grant from Chiesi Pharmaceuticals S.p.A.. These companies produce surfactants or surfactant proteins, but had no role in design, preparation, review, approval of the manuscript, or decision to submit it for publication. The declared conflicts are all unrelated to the present manuscript. The other authors have no conflicts of interest to disclose.
Free to read: This content has been made available to all.